Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 7c, updates guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.37 -0.56%
EPS Growth %: -60.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: -60.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $50.75 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2024 revenue of $190-210 million, versus the consensus of $197.4 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
- Designer Brands (DBI) PT Lowered to $6 at UBS
- lululemon athletica (LULU) call put ratio 1 call to 1.3 puts into quarter results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
